|
Overview - Day 1
Saturday and Sunday, August 12-13
|
A Special Invitation to a Hands-On Workshop
August 12-13 • Tufts University School of Engineering
|
|
Skills for Advancing Stem Cell and Tissue Modeling Research
Program Director: David L. Kaplan, Ph.D., Professor & Chair, Department of Biomedical Engineering; Professor, Department of Chemical & Biological Engineering; Director, Bioengineering & Biotechnology Center, Tufts University
As a CELLutions Summit delegate you're invited to attend this Hands-On Workshop organized by the Tissue Engineering Resource Center
(TERC) at Tufts University.
Note - Limited space is available. All
payments must be paid in full to process your registration. For further information please visit
www.ase.tufts.edu/terc
Click here to
download TERC agenda
|
Sorry,
This workshop is Sold Out.
To join the waitlist please contact CHI's registration dept. at
781-972-5400 |
|
Sunday, August
13
5:00-6:00pm Early Registration
Monday, August 14
7:30am Registration and Morning
Coffee
STEM CELL CULTURE, EXPANSION, SOURCES
8:15 Chair’s Opening Remarks
|
Plenary Keynote Presentations |
|
|
8:30 Therapy with Cultured Cells: Successes, Failures, the Road to Improvement and the Future of Human Embryonic Stem Cells
Howard Green, Ph.D., George Higginson Professor of Cell Biology, Department of Cell Biology, Harvard Medical School
There are few examples of successful use of cultured cells for therapeutic tissue regeneration. The first such example was the
keratinocyte, which has enjoyed broad but not always successful application. It is now clear that in order to be successful, a graft must contain an adequate number of stem cells, and criteria exist for determining that number. Keratinocytes derived from human embryonic stem cells differ appreciably from post-natal
keratinocytes, and these differences affect our thinking about therapeutic use of other somatic derivatives of hES cells. |
|
|
|
|
9:20 Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population
Harvey F. Lodish, Ph.D., Professor of Biology and Bioengineering, MIT and Member, Whitehead Institute for Biomedical Research
We uncovered a novel fetal liver CD3+Ter119- cell population that supports ex vivo expansion of hematopoietic stem cells. DNA array experiments showed that, among other proteins, insulin-like growth factor 2 (IGF-2),
angiopoietin-like 2, (Angptl2) and angiopoietin-like 3 (Angptl3) are specifically expressed by these cells. When highly enriched HSCs were cultured in the presence of IGF-2, Angptl2 or Angptl3 together with saturating levels of other growth factors for 10 days, a > 25- fold net expansion of long-term HSCs was observed by long- term bone marrow reconstitution analysis. And in collaboration with members of Susan Lindquist’s laboratory we showed that all long- term repopulating HSCs express the prion protein and that HSCs from PrP null bone marrow exhibited impaired self-renewal in serial competitive transplantation experiments, and premature exhaustion when exposed to cell cycle-specific myelotoxic injury. Ongoing studies will define the precise role PrP plays in hematopoietic stem cell biology. |
|
 |
10:00 Is There a Conflict Between Commercial Interests and the Progress of Science?
Moderator: Ann Kiessling, Ph.D., Harvard Medical School
Dr. Paul J. Price, Research Fellow and Chief Scientific Officer, GIBCO Cell Culture Research and Development, Invitrogen
John Biggers, D.Sc., Ph.D., Harvard Medical School
Mr. John Iwanicki, Patent Attorney, Legal, Banner & Witcoff Ltd.
Morey Krause, Ph.D., Founder Vice President & Chief Technology Officer, ViaCell Inc.
Howard Green, Ph.D., George Higginson Professor of Cell Biology, Department of Cell Biology, Harvard Medical School
Three issues plague scientists and industry today as we all strive to improve mammalian cell culture. At the core of these issues is finding the right formulation(s) and composition (supplements) to facilitate necessary troubleshooting to move through bottlenecks. They are based on the limitations regarding formulation disclosures, amplifying with differentiation and amplifying to support cell growth. Can industry and scientist work together to find common ground?
|
11:00 Coffee Break, Poster and Exhibit Viewing
12:00 Lunch Break – Technology Workshops (Sponsorships Available)
CULTURING, SUBCULTURING & SUPPORTING
CELLS & TISSUES
1:30 Chair’s Remarks
1:35 Nutritional Requirements of Mammalian Cells in Culture: Design and Optimization of the Cell Culture Medium
Paul J. Price, Ph.D., GIBCO Invitrogen
A classical cell culture medium is made up of a buffered isotonic salt solution supplemented with vitamins, amino acids, a source of energy such as glucose or glutamine and a protein supplement such as serum. As the science of media formulation progressed from serum-supplemented to serum-free and then to chemically-defined, substitutes for the serum component and then for serum derived proteins had to be found. Many segments of Industry are presently moving away from media and reagents containing any component of animal or human origin. The outbreak of BSE and CJV in England heightened the awareness of the risk of contamination of therapeutics by prions or viruses and prompted regulatory pressure for companies to address this potential risk. This teaching seminar will cover the basics of a cell culture medium and the advantages and disadvantages of the serum supplement. It will then progress into the construction of serum-free and chemically defined formulations and then to the elimination of all components of animal origin. Ways to optimize both cell growth and productivity will be presented as well as the design of media for specific applications. Emphasis will be placed on reducing apoptosis by controlling osmolality, ammonia, and free radical production and through optimization of the media formulation.
2:05 Derivation of Human Embryonic Stem Cell Lines in Defined Conditions
Mark Levenstein, Ph.D., Assistant Scientist, Biochemistry, WiCell Research Institute
The promise of human embryonic stem cells for medical therapeutics depends on the ability to develop tightly controlled culture conditions whose manipulation results in desired cell phenotypes. TeSR1 is a fully defined pluripotency medium solely comprising human or recombinant gene products. To explore its utility two new human embryonic stem cell lines were derived in TeSR1 and cultured exclusively on human matrix proteins. Furthermore, TeSR1 effectively removes reported animal modifications to existing human embryonic stem cell lines. The introduction of defined, humanized medium should accelerate the progression of human embryonic stem cell research from the bench top to the clinic.
2:35 Human Embryonic Germ Cell
Lines
Dr. Helmuth HG Van Es, Chief Scientific Officer, Stem Cell Innovations
We have established ten independent human embryonic germ cell lines from fetal tissue. These lines have been developed without the use of feeder layers and are relatively straightforward to culture and passage. They display the markers of pluripotent cells and can be differentiated into multiple cell types
in vitro.
3:05 Refreshment Break, Poster and Exhibit Viewing
3:45 Throughput Screening Strategies for Human Primary Cells
Dr. David Fischer, Team Leader, BioFocus
Target discovery programs are increasingly focusing on the screening of primary human cells, since this will yield more relevant targets. Through our adenoviral technology, we have made high throughput screening in human primary cells feasible. We have established expertise in target discovery projects using primary cell cultures, which mimic the biology of the disease as closely as possible. Several examples of target discovery programs in primary cells will be presented and technical issues on the use of primary cells in high-throughput discovery programs will be discussed.
4:15 Optimizing Stem Cell Discovery Through Rigorous Quality Control Lessons from Clinical Embryology Laboratories
James Trimarchi, Ph.D., Director Department: Six-sigma Quality Management, Trimarchi Healthcare Consulting
Quality initiatives in clinical embryology laboratories have greatly improved the survival of gametes and embryos in culture and can be adapted to optimize stem cell laboratories. Clinical application of stem cell therapies will require compliance with federal standards for sample handling, quality control and quality assurance. Methodologies developed for clinical embryology laboratories can be used as a framework to enhance the effectiveness, efficiency and regulatory compliance of stem cell laboratories.
|
4:45 Optimized Stem Cell Derivation, Culture and Screening – Imagining the Future
James Trimarchi, Ph.D.
Mark Levenstein, Ph.D.
Dr. David Fischer
Dr. Yury Verlinsky
John Hambor, Ph.D.
Dr. Helmuth HG Van Es
James H. Kelly, Ph.D.
It is unlikely that future systems for stem cell derivation, culture and screening will employ the cumbersome and labor intensive methods presently being used during the discovery phase of stem cell therapeutics. Panel members will lead a discussion imaging future technologies that could facilitate the commercialization and clinical application of stem cells. The audience will be encouraged to participate to drill-down into the primary hurdles for effective stem cell application.
|
5:15 CELLutions SUMMIT Networking Reception
6:30 Close of Day
For more conference information, please contact:
Shelley W. Amster, Conference Producer
Phone: 617 630-1373
E-mail: samster@healthtech.com
For exhibit and sponsorship information, please contact:
Carol Dinerstein, Sales Manager
Phone: 781-972-5471
E-mail: dinerstein@healthtech.com |
|
